Our goal is to minimize the impact of stroke on our patients’ lives. We are at the forefront of identifying new approaches to prevent and treat stroke, and to promote recovery after it has occurred. Our investigators are involved in a number of clinical trials and investigational studies at our Manhattan and Brooklyn locations.
One area of research is identifying treatments that best prevent stroke from recurring. Our studies are investigating pharmacologic treatments, such as blood thinners, and non-pharmacologic treatments, such as continuous positive airway pressure (CPAP) devices for sleep apnea. Our studies are also analyzing large patient datasets from multiple centers to identify factors that increase the risk of stroke.
Another area of research is in the acute treatment of stroke. Our studies are investigating new treatment strategies to minimize damage to the brain. These include pharmacologic treatments to reduce brain swelling after large strokes and identifying genetic risk factors for recurrent hemorrhage with certain medications.
A third area of research is in recovery after stroke. Our studies are identifying brain pathways that reorganize after damage, so that they can be targeted to boost recovery. Our studies are also developing novel devices to precisely measure rehabilitation training, so that we can deliver the intensive training the brain needs to rewire after stroke.
Our research is funded by the National Institutes of Health (NIH), the American Heart/Stroke Association, and other foundations. NYU Langone’s Tisch Hospital and NYU Langone Hospital—Brooklyn are participating centers in the NIH’s StrokeNet research collaboration. StrokeNet is a network of more than 500 hospitals across the United States that serves as the pipeline for potential new treatments for people with stroke and those at risk for stroke.